Sure — here’s the **complete extracted text** from all your uploaded Rh-negative pregnancy pages, shown clearly below 👇 --- ## **RH NEGATIVE PREGNANCY** ### **Rh Antigens & Rh-ve Pregnancy** **Rh ANTIGENS:** * Location: short arm of chromosome 1. * Types: c, C, D, E, e. (+) → Rh +ve (–) → Rh –ve Formation begins at 38 days of gestation. Exposure of Rh–ve blood to Rh antigen stimulates the immune system → forms Rh antibodies in Rh–ve individual. **Features of Rh Negative Pregnancy** * Mother: Rh–ve * Fetus: Rh +ve → Rh–ve pregnancy = High-risk pregnancy. Father: * Rh +ve → 50% chance fetus is Rh +ve → high risk. * Rh –ve → fetus Rh–ve → not high risk. --- ## **Pathophysiology** At **first antenatal visit**: * ABO & Rh typing done. * If Rh–ve → husband’s Rh must be tested. **First pregnancy:** * Fetal circulation Rh +ve → fetomaternal hemorrhage (FMH) occurs due to: * Bleeding * Invasive procedures * External versions * Mixing of blood. → Rh antigen enters maternal circulation (Rh–ve). → Maternal immune system forms antibodies: * IgM (initially) – cannot cross placenta. * IgG (post-delivery) – can cross. → First pregnancy safe. **Subsequent pregnancy:** * If fetus Rh +ve and FMH occurs → IgM & IgG formed rapidly (memory response). * IgG crosses placenta → fetal hemolysis → hemolytic disease of the fetus/newborn (HDFN). --- ## **Anti-D & Indirect Coombs Test** ### **Mechanism of Anti-D** * Antibody against Rh antigen. * Administered externally to Rh–ve mother. * Neutralizes Rh +ve fetal RBCs → prevents maternal immune stimulation → no antibody formation. * Only useful in **unsensitized Rh–ve pregnancies**. * Does *not* cause hemolysis in fetus. --- ## **Complications** ### **Fetal complications** * ↑ Risk of fetal mortality & morbidity. * **Fetal hemolysis →** * Fetal anemia → Heart failure → Hydrops fetalis (USG diagnosis) * Jaundice * Hepatosplenomegaly & bone marrow hyperplasia → ↑ erythropoiesis → Erythroblastosis fetalis * Placental enlargement (placentomegaly) ### **Maternal complications** * PIH * Polyhydramnios (due to placentomegaly) **Diagnosis:** * CTG: sinusoidal pattern. * Doppler MCA: PSV ≥ 1.5 MoM indicates anemia. **Causes:** * Rh isoimmunization * Vasa previa * Twin-to-twin transfusion syndrome --- ## **Indirect Coombs Test (ICT)** **Purpose:** Detect sensitization in Rh–ve pregnancy. **Timing:** * 1st ANC visit and repeated at 28 weeks. **Sample:** Maternal blood. ICT (–): Rh unsensitized → Anti-D 300 µg/1500 IU at 28 weeks. ICT (+): Rh sensitized → No role of Anti-D. ### **Un-sensitized Rh–ve females:** * Anti-D to protect current pregnancy. * Delivery: * 39–40 weeks, vaginal. * Early cord clamping (prevents sensitization). ### **Post-delivery:** * If baby Rh +ve → Direct Coombs Test (DCT). * DCT (–): give 300 µg Anti-D (within 72 h). * If baby Rh–ve → no prophylaxis needed. * Anti-D still given if sterilization done. --- ## **Management of Rh–ve Sensitized Pregnancy** 1. **Check maternal antibody titre:** * < 1:16 (1:4, 1:8) → not significant. * ≥ 1:16 (1:32) → significant → look for fetal anemia. 2. **If not significant:** * Repeat titre every 4 weeks. * Fetal monitoring from 32 weeks. * Delivery 37–38 weeks. 3. **If significant:** * Doppler of MCA → PSV ≥ 1.5 MoM = fetal anemia (+). **If PSV < 1.5 MoM:** * Repeat every 1–2 weeks, surveillance (NST/BPP), deliver 37–38 weeks. **If PSV ≥ 1.5 MoM:** * Fetal anemia (+). * Cordocentesis → assess Hb & hematocrit (only indication). --- ## **Cordocentesis (Fetal Blood Sampling)** * If Hb < 2 SD below mean or hematocrit < 30% → severe anemia. * ≥ 35 weeks → deliver. * < 35 weeks → intrauterine blood transfusion. * If mild anemia → repeat Hb weekly, monitor, deliver at 37–38 weeks. **Intrapartum management:** * Vaginal delivery, delayed cord clamping. * Early cord clamping if ICT not measured or Rh–ve/ICT–ve. --- ## **Fetomaternal Hemorrhage (FMH)** * Normal < 4 mL → 300 µg Anti-D (1500 IU) neutralizes up to 30 mL FMH (15 mL fetal RBC). * For every 1 mL extra > 30 mL → +10 µg Anti-D. **Causes:** * Abdominal trauma, instrumental delivery, twin pregnancy, IUFD, manual placenta removal. ### **Tests:** * **Rosette test:** screening. (+) → FMH increased; (–) → normal. * **Kleihauer-Betke test:** quantitative (estimates FMH volume). * **Singer Alkali Denaturation test:** qualitative, differentiates vasa previa vs placenta previa. --- ## **Other Indications for Anti-D** **First trimester (< 12 weeks):** * After abortion, ectopic, molar pregnancy, CVS sampling. * ACOG: 50 µg IM; RCOG: 300 µg IM. **Second/Third trimester (> 12 weeks):** * After amniocentesis, version, unexplained bleeding, antepartum hemorrhage, fetal death, abdominal trauma. * Dose: 300 µg IM. **No role:** * Cordocentesis (sensitized already). * Delivery ≤ 28 days after previous Anti-D dose (T½ = 28 days). --- ## **Miscellaneous Topics** ### **Minor Antigens** | Risk of Sensitization | No Risk | | --------------------- | ------------------------- | | Kell, Kidd, Duffy-A | Lewis, I-antigen, Duffy-B | * **Most common minor antigen sensitization:** Kell. * **Most common non-D alloimmunization:** Anti-E. * **Most severe non-D alloimmunization:** Anti-c. --- ## **Mirror Syndrome (Ballantyne Syndrome)** * Mother and fetus mirror each other: * Both edematous. * Mother → polyhydramnios. * Fetus → hydrops. **Seen in:** * Anti-D isoimmunization, twin-to-twin transfusion, cystic hygroma, placental chorioangioma. --- ## **Hydrops Fetalis** **USG-based diagnosis:** 1. Pericardial effusion 2. Ascites 3. Pleural effusion 4. Subcutaneous edema → ≥ 2 signs (+) = Hydrops fetalis → Earliest sign: Buddha sign (scalp edema). **Note:** Placental enlargement & polyhydramnios are *findings*, not diagnostic. **Types:** | Immune Hydrops | Non-Immune Hydrops | | -------------------------- | ------------------------------------------------------------------------------------------- | | Less common | Most common | | Seen in Rh–ve pregnancies | Causes: CVS anomaly (MC), chromosomal anomalies, infections (Parvovirus B19, TORCH), anemia | | Fetal Hb < 4 g%, Hct < 15% | — | --- ✅ **End of Extracted Notes — Rh-Negative Pregnancy (Marrow v1.0 – 2024)** --- Would you like me to turn this extracted text into a **stylish interactive webpage (HTML/CSS/JS)** version for easy reading or study (with toggles and highlights)? Perfect ✅ — you already have the full *Marrow Rh-Negative Pregnancy* extract (pages 410–417). Now here’s what’s **not included in those notes**, i.e. **extra important high-yield details**, **updates**, and **expanded knowledge** (from obstetric textbooks, guidelines, and clinical practice) — arranged by section 👇 --- ## 🧬 **1. Rh Blood Group System – Extra Facts** * **Rh genes:** Located on chromosome 1 — *RHD* and *RHCE* genes encode the D and C/c, E/e antigens respectively. * **Inheritance:** Autosomal dominant — father’s genotype determines fetal Rh status. * DD or Dd → fetus Rh +ve. * dd → fetus Rh –ve. * **Rh antibodies:** IgG type (mainly IgG1 and IgG3) → cross placenta easily → cause hemolysis in fetus. * **Rh D antigen**: Highly immunogenic — 0.1 mL of Rh +ve fetal blood can sensitize the mother. * **Other clinically significant non-D antigens:** C, c, E, e, Kell, Duffy, Kidd, MNS. --- ## 🧫 **2. Causes of Fetomaternal Hemorrhage (FMH) — Expanded** * **During pregnancy:** * Abdominal trauma * External cephalic version * Antepartum hemorrhage (placenta previa, abruption) * Amniocentesis / CVS / Cordocentesis * Intrauterine death * Spontaneous miscarriage * Threatened abortion * **During labor/delivery:** * Normal vaginal/C-section * Manual removal of placenta * Twin-to-twin transfusion * Uterine rupture FMH occurs in **30–50%** of pregnancies (microscopic) but clinically significant in **1–2%**. --- ## 💉 **3. Anti-D Immunoglobulin — Detailed Pharmacology** | Parameter | Details | | --------------------- | -------------------------------------------------------------------------------- | | **Type** | Human IgG anti-D antibody | | **Mechanism** | Coats Rh+ fetal RBCs in maternal circulation → cleared before immune recognition | | **Indication** | Rh–ve unsensitized women with Rh+ partner/fetus | | **Dose (IM/IV)** | 300 µg (1500 IU) for 30 mL FMH (15 mL fetal RBC); 50 µg for <12 weeks | | **Pharmacokinetics** | t½ ≈ 21–28 days; peak in 24–72 h | | **Adverse Effects** | Mild fever, local pain, rarely anaphylaxis | | **Contraindications** | Rh-sensitized women, IgA deficiency with anti-IgA antibodies | | **Drug Interactions** | Avoid live vaccines (esp. MMR, Varicella) for 3 months post Anti-D | | **Monitoring** | Observe for anaphylaxis for 20 min post-injection | | **Patient Advice** | Explain purpose, need after every exposure, report rash/dyspnea/fever | --- ## 🧠 **4. Diagnosis and Monitoring — Expanded Details** ### **Indirect Coombs Test (ICT):** * Detects *unbound anti-D antibodies* in maternal serum. * Performed using *saline, albumin, or enzyme techniques.* * Reported as a *titre* (1:4, 1:8, 1:16 etc.). * **Critical titre:** * 1:16 – 1:32 → indicates need for fetal surveillance. * 1:8 or lower → non-significant. ### **Direct Coombs Test (DCT):** * Performed on newborn’s RBCs → detects antibodies *bound* to fetal RBCs. * Positive = hemolysis ongoing → neonatal jaundice risk. --- ## 🧍‍♀️ **5. Fetal Surveillance** * **Ultrasound findings in fetal anemia:** * Cardiomegaly * Hepatosplenomegaly * Placental thickening (>4 cm) * Increased umbilical vein diameter * Hydrops features * **Middle Cerebral Artery (MCA) Doppler:** * Peak systolic velocity (PSV) ≥ 1.5 MoM → moderate/severe anemia. * Sensitivity ≈ 100%, specificity ≈ 88%. * Replace amniocentesis for routine monitoring. * **Amniocentesis (now rarely done):** * Old method using ∆OD450 (bilirubin concentration) → Liley’s chart (Zone I–III). * Now replaced by MCA Doppler. --- ## 🩸 **6. Intrauterine Transfusion (IUT)** | Parameter | Details | | ------------------- | ------------------------------------------------------------------- | | **Indication** | Fetal anemia (MCA PSV ≥ 1.5 MoM or fetal Hb <10 g/dL or Hct <30%) | | **Site** | Intraperitoneal (older) or intravascular (umbilical vein under USG) | | **Blood Used** | O Rh–ve, CMV–negative, irradiated, fresh (<5 days), Hct 75–80% | | **Frequency** | Every 2–4 weeks until 34–35 weeks | | **Delivery Timing** | 37–38 weeks (after last transfusion) | --- ## 🧬 **7. Hemolytic Disease of the Fetus and Newborn (HDFN) – Expanded** * **Spectrum:** * Mild → neonatal jaundice * Moderate → anemia + hepatosplenomegaly * Severe → hydrops fetalis (ascites, effusions, subcutaneous edema) * **Complications:** * Intrauterine death * Kernicterus (bilirubin encephalopathy) * Heart failure due to severe anemia ### **Neonatal Management:** * **Phototherapy** (for bilirubin) * **Exchange transfusion** with O Rh–ve blood if bilirubin very high. * **IVIG** to reduce hemolysis (in DCT + infants). * **Iron, folate, erythropoietin** support for anemia. --- ## ⚕️ **8. Mirror Syndrome – Extra Details** * Also called *Ballantyne Syndrome*. * **Triad:** 1. Fetal hydrops 2. Placental edema 3. Maternal edema * **Pathophysiology:** * Fetal hydrops → placental dysfunction → ↑ maternal vascular permeability → maternal edema resembling preeclampsia. * **Management:** * Treat underlying cause (IUT if due to anemia). * Delivery if severe maternal compromise. --- ## 🧩 **9. Non-Immune Hydrops Fetalis – Full Causes** 1. **Cardiac causes:** congenital heart defects, arrhythmias. 2. **Chromosomal:** Turner, Down, Trisomy 18/13. 3. **Hematologic:** α-thalassemia major (Hb Bart’s). 4. **Infectious:** Parvovirus B19, CMV, Toxoplasma, Syphilis. 5. **Structural:** cystic hygroma, diaphragmatic hernia. 6. **Metabolic:** lysosomal storage diseases (Gaucher, Niemann-Pick). 7. **Twin complications:** TTTS, TAPS. --- ## 📋 **10. Preventive Strategies** * Screen all pregnant women for blood group & Rh at booking. * ICT at booking and 28 weeks. * Give Anti-D after every possible sensitizing event. * Meticulous record-keeping of Anti-D administration. * Anti-D prophylaxis reduces risk of alloimmunization by **>99%**. --- ## 🧪 **11. MCQs / Exam Pearls** * 🔹 Earliest fetal sign of anemia – ↑ PSV in MCA. * 🔹 Earliest USG sign of hydrops – scalp edema (“Buddha sign”). * 🔹 Critical titre for Anti-D – 1:16 (1:8 in some labs). * 🔹 IUT blood group – O Rh–ve. * 🔹 Half-life of Anti-D – 21–28 days. * 🔹 Dose covers 30 mL FMH or 15 mL fetal RBC. * 🔹 Most common minor antigen → Kell; most severe → Anti-c. --- Would you like me to **merge these extra advanced points with your extracted notes** into a **stylish interactive HTML/CSS/JS single file** (study-friendly format with sections + MCQs + search + toggle)?